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 CURRENTOPINION Curing advanced melanoma by 2025
Reinhard Dummer, Simone M. Goldinger, Verena Paulitschke, and
Mitchell P. Levesque
Purpose of review
To outline the most urgent challenges in the management of advanced melanoma.
Recent findings
Considerable progress in targeted and immunotherapy of advanced melanoma has opened a perspective
for a cure if all molecular and medical information is integrated in a rational precision treatment algorithm.
Summary
Bioinformatics and system biology approaches will be needed to deal with omics databases. The support
of patient advocacy groups may help to increase the acceptance of large scale, routine biobanking.
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After decades of stagnation, targeted therapy and
immunotherapy have dramatically improved the
outcome of metastatic melanoma treatment. The
combination of BRAF and MEK inhibitors achieves
response rates of 70%, with progression-free survival
of approximately 10months. These treatments have
further enhanced the overall survival in comparison
to monotherapy with a BRAF inhibitor [1–3]. How-
ever, resistance is still problematic [4]. In this issue,
McArthur and colleagues discuss the mode of action
and perspective of cyclin-dependent kinase inhibi-
tors. There is evidence that resistance during the
inhibition of the mitogen-activated protein kinase
pathway can be delayed by the combination of
BRAF–MEK inhibitors with cyclin-dependent kinase
inhibitors [5,6]. If the tolerability of these triple
therapies will be as acceptable as the combination
therapy, we might expect additional benefit for this
approach.
Monoclonal antibodies interfering with check-
point inhibitors on the surface of T cells, dendritic
cells, or tumor cells such as anti-cytotoxic T-lympho-
cyte-associated protein-4 antibodies and anti-
programmed cell death protein 1 (PD1) antibodies
have revolutionized immunotherapy for melanoma
and are currently evolving into promising appro-
aches for other malignancies.
For decades, there has been an ongoing interest
in immunotherapy based on the clinical obser-
vations of spontaneous regressions associated with
T-cell infiltrates. However, there were a number of
very frustrating clinical trials using vaccines, den-
dritic cell approaches, or cytokine therapies [7].
Very recently, prospective randomized con-
trolled trials demonstrated that immunotherapy
with the two anti-PD1 antibodies pembrolizumab
and nivolumab has higher response rates, longer
response durations, and less severe adverse events
than the chemotherapy used in this clinical situ-
ation [8]. There are signals from phase I and II
clinical trials that the efficacy of anti-PD1 antibodies
can be further increased by the addition of ipilimu-
mab. If the early data of a 1-year survival rate ofmore
than 80% and the 2-year survival rate of more than
70% can be confirmed in prospective randomized
trials, then the combination of the two checkpoint
inhibitors ipilimumab and nivolumab will be a very
promising first-line therapy for advanced metastatic
melanoma. However, in contrast to anti-PD1mono-
therapy, this combined immunotherapy approach
is associated with a number of severe typically
immune-related adverse reactions that can become
life threatening if not recognized and not treated
early with rigorous immunosuppression using cor-
ticosteroids and TNF-alpha antagonists [9].
The availability of different promising thera-
peutic approaches demands an intensive search
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for predictive biomarkers that better stratify patients
for the respective treatment. For targeted therapy,
the presence of a BRAF or NRAS mutation gives the
rational basis for the first-treatment interventions
using a BRAF and MEK inhibitor, combination, or a
MEK inhibitor monotherapy. However, in order to
optimize therapy and to prevent early resistance,
additional mutations might be considered. In the
near future, at least targeted deep exon sequenc-
ing will be available for the majority of patients.
Clinicians will have to learn how to integrate these
molecular data into treatment decisions.
Predictive markers for immunotherapy are also
on the horizon, but still need confirmation in
clinical trials. Obviously, the situation for immuno-
therapy will be even more complex. We expect that
no single parameter will predict immune suscepti-
bility, but rather a matrix of clinical and immuno-
logical factors in the tumor microenvironment
or present systemically may provide the strongest
predictive power of a patient’s potential response
to immunotherapy. In this context, integrating
immune therapy markers and molecular features,
such as neo antigens, will be critical [10].
As the understanding of melanoma progression
becomes increasingly more complex, omics data-
bases will play a more important role in patient
stratification strategies and future scientific endeav-
ors to develop novel therapies. Thus, these chal-
lenges will require intensive cooperation with
bioinformaticians and system biology experts who
know how to integrate systems-level measurements
of genetic and epigenetic alterations, transcriptional
profiles, and proteomics data into predictive or
targetable pathways. This comprehensive molecular
understanding must result in a more complex
description of the patient’s tumor that gives a
rational basis for individual treatment decisions
facilitating a multidimensional precision medicine
approach.
Obviously, the decisionmatrixmust be based on
the self-learning programs that integrate the out-
comes of earlier experience into the decision-
making process in order to provide clinicians with
the best possible options for their patients.
As many melanoma patients whose primary
tumors are excised today will metastasize only in
5–20 years, the primary tumors collected today are
already of tremendous relevance for the individual
patient. Therefore, all academic centers should
initiate biobank approaches and try to collect
primary tumors for these centralized biobanks.
Unfortunately, primary tumors today are often
removed by private practitioners or surgeons and
sent to private pathology laboratories that do not
preserve the tumor tissue longer than legally
necessary. Therefore, we have initiated a biobank
project at the University Hospital Zurich that is able
to collect primary tumors in cooperation with pri-
vate dermatopathology laboratories in the area.
Patient advocacy groups also play an important
role in bringing more effective treatments to the
clinic. Melanoma survivors are founding increas-
ingly stronger and better organized advocacy
groups, and the improved outcomes of newly avail-
able therapies will foster the growth of these groups.
However, the socioeconomic and political environ-
ment regulating clinical research and biobanking is
challenging. Academic physicians at university clin-
ics face more andmore legal hurdles that slow down
their work. For example, even small retrospective
studies now require specific ethical approval, which
leads to increased workloads for both researchers
and ethical committees and delays the pace of
ground-breaking research. Although these laws are
an important instrument to protect patients’ rights,
a better balance must be struck that both ensures
those rights and encourages the development of the
next therapy that may save thousands of lives.
When patients understand that they may directly
benefit from clinical and translational cancer
research, they are eager to cooperate and to support
clinical research teams. However, there is a need for
a constant exchange of information and ideas
between patient advocacy groups and clinical
researchers as well as translational cancer biologists.
In addition, patient-related outcome such as the
quality of life will get more and more important.
In contrast to the earlier studies, quality-of-life proj-
ects are now accompanying many large phase III
clinical trials [11].
In summary, we feel lucky to have everything in
our hands: new powerful drugs and high-through-
put molecular tools to better understand tumor
tissues. Sophisticated immunology research has
highlighted the essential checkpoints and targets
for immunotherapy, and bioinformaticians and
computational biologists can help to model these
huge datasets. We must convince our patients and
regulating authorities that biobanking and systems-
level analyses of larger patient cohorts during
targeted approaches and immune therapy can create
rational algorithms that will optimize treatment
success and improve the lives of our patients.
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